Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer
Authors
Oliveira, M.Hamilton, E. P.
Incorvati, J.
de la Heras, B. B.
Calvo, E.
Garcia-Corbacho, J.
Ruiz-Borrego, M.
Vaklavas, C.
Turner, N. C.
Ciruelos, E. M.
Patel, M. R.
Armstrong, Anne C
Kabos, P.
Twelves, C.
Brier, T.
Irurzun-Arana, I.
Klinowska, T.
Lindemann, J. P. O.
Morrow, C. J.
Baird, R. D.
Affiliation
Vall d'Hebron Institute of Oncology (VHIO), Barcelona,Issue Date
2022
Metadata
Show full item recordCitation
Oliveira M, Hamilton EP, Incorvati J, de la Heras BB, Calvo E, Garcia-Corbacho J, et al. Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300091.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.1032Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.1032Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.1032